BioCentury
ARTICLE | Clinical News

Opdivo-Yervoy combo beats Yervoy alone in melanoma study

April 21, 2015 1:38 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) said the combination of Opdivo nivolumab plus Yervoy ipilimumab was superior to Yervoy alone in the Phase II CheckMate -069 trial to treat treatment-naive patients with advanced melanoma.

Opdivo plus Yervoy led to an objective response rate (ORR) of 61% vs. 11% with Yervoy (p<0.001), meeting the trial's primary endpoint. The combination led to complete responses in 22% of patients without BRAF mutations (n= 72) as well as 22% of patients with BRAF mutations (n=23) vs. no CRs in the Yervoy group. ...